Vitura HealthASX:VIT EBITDA Margin % is 2.22% as of Dec. 2025, which is 64% below its 10-year median of 6.09. The stock has 8 warning signs investors should review. Among 956 Drug Manufacturers companies, Vitura Health ranks worse than 69.35% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vitura Health's EBITDA for the
six
months ended in Dec. 2025 was A$1.5 Mil. Vitura Health's Revenue for the
six
months ended in Dec. 2025 was A$67.9 Mil. Therefore, Vitura Health's EBITDA margin for the quarter that ended in Dec. 2025 was 2.22%.
Vitura Health (ASX:VIT) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vitura Health EBITDA Margin % Related Terms
Vitura Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vitura Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vitura Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitura Health EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vitura Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vitura Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitura Health (ASX:VIT) has a EBITDA Margin % of 2.22% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vitura Health and its competitors. This is 64% below median its historical median of 6.09. According to the industry distribution chart, Vitura Health ranks #663 out of 956 companies in the Drug Manufacturers industry, placing it in the top 69.4%.
Is Vitura Health's EBITDA Margin % too high?
Vitura Health's current EBITDA Margin % of 2.22% is 64% below median its 10-year median of 6.09. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Vitura Health's value of 2.22% is 82.3% below this industry median. Based on the distribution chart, Vitura Health ranks #663 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Vitura Health's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vitura Health ranks #663 out of 956 companies for EBITDA Margin %. This places Vitura Health in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Vitura Health's value of 2.22% is 82.3% below this benchmark. While the company's 10-year median is 6.09 vs. the industry median of 12.52, Vitura Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitura Health's current EBITDA Margin % of 2.22% is 82.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vitura Health and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitura Health's current EBITDA Margin % is 2.22%, which is 64% below median its own 10-year median of 6.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitura Health stock overvalued right now?
Based on GuruFocus' analysis, Vitura Health (ASX:VIT) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.10, compared to a current price of A$0.03 — trading 73% below its estimated fair value. The current EBITDA Margin % is 2.22%, which is 64% below median its 10-year median of 6.09 and 82.3% below the Drug Manufacturers industry median of 12.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vitura Health (ASX:VIT), the current EBITDA Margin % is 2.22% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vitura Health Ltd is focused on creating medicinal cannabis products and digital health solutions that connect and strengthen the ecosystem between patients, prescribers, pharmacists, and suppliers. The company has two business segments namely, Sales and distribution (involving the sale and distribution of medical products including medicinal cannabis, psychedelic drugs, and smoking cessation products) and Clinics and services (involving the operation of medicinal cannabis clinics and the provision of related services). The company generates the majority of its revenue from the Sales and distribution segment. Geographically the company generates the majority of its revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VIT has been successfully added to your 